Novel nomogram to predict risk of bone metastasis in newly diagnosed thyroid carcinoma: a population-based study

BMC Cancer. 2020 Nov 3;20(1):1055. doi: 10.1186/s12885-020-07554-1.

Abstract

Background: The aim of this study was to develop and validate a visual nomogram for predicting the risk of bone metastasis (BM) in newly diagnosed thyroid carcinoma (TC) patients.

Methods: The demographics and clinicopathologic variables of TC patients from 2010 to 2015 in the Surveillance, Epidemiology and End Results (SEER) database were retrospectively reviewed. Chi-squared (χ2) test and logistic regression analysis were performed to identify independent risk factors. Based on that, a predictive nomogram was developed and validated for predicting the risk of BM in TC patients. The C-index was used to compute the predictive performance of the nomogram. Calibration curves and decision curve analysis (DCA) were furthermore used to evaluate the clinical value of the nomogram.

Results: According to the inclusion and exclusion criteria, the data of 14,772 patients were used to analyze in our study. After statistical analysis, TC patients with older age, higher T stage, higher N stage, poorly differentiated, follicular thyroid carcinoma (FTC) and black people had a higher risk of BM. We further developed a nomogram with a C-index of 0.925 (95%CI,0.895-0.948) in the training set and 0.842 (95%CI,0.777-0.907) in the validation set. The calibration curves and decision curve analysis (DCA) also demonstrated the reliability and accuracy of the clinical prediction model.

Conclusions: The present study developed a visual nomogram to accurately identify TC patients with high risk of BM, which might help to further provide more individualized clinical decision guidelines.

Keywords: Nomogram; SEER database; Thyroid carcinoma; bone; metastasis; risk factors.

MeSH terms

  • Adenocarcinoma, Follicular / pathology*
  • Age Factors
  • Bone Neoplasms / diagnosis*
  • Bone Neoplasms / secondary*
  • Female
  • Humans
  • Logistic Models
  • Male
  • Neoplasm Staging
  • Nomograms*
  • Precision Medicine
  • Reproducibility of Results
  • Retrospective Studies
  • Risk Assessment
  • SEER Program
  • Thyroid Neoplasms / pathology*